NeoPharm Co Ltd
NeoPharm Co Ltd is a personal products company that generates revenue primarily through the production and sale of personal care products.
Business. NeoPharm Co Ltd (092730.KQ) is a personal products company operating within the Consumer Non-Cyclicals sector. The firm is primarily engaged in the sale of personal care items and is listed on the KOSDAQ exchange. Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not available in the provided data. Consequently, the company is described at the industry level as a participant in the personal products market.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
NeoPharm Co Ltd (092730.KQ) is a personal products company operating within the Consumer Non-Cyclicals sector. The firm is primarily engaged in the sale of personal care items and is listed on the KOSDAQ exchange. Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not available in the provided data. Consequently, the company is described at the industry level as a participant in the personal products market.
NeoPharm maintains a strong liquidity position with a current ratio of 8.4 and a low debt-to-equity ratio of 0.01, indicating minimal reliance on debt financing and a robust balance sheet. The company's cash and equivalents amount to 26,824,586,090 KRW, which supports its operational flexibility and capacity to fund future growth initiatives.
In terms of profitability, NeoPharm demonstrates a return on equity (ROE) of 14.24% and a return on assets (ROA) of 12.77%, both of which exceed the typical benchmarks for the personal products industry. These metrics suggest that the company is effectively utilizing its equity and assets to generate profits.
The company's revenue is concentrated within the personal care products segment, with no disclosed geographic diversification. This concentration may expose the company to regional economic fluctuations and market-specific risks, although the lack of geographic breakdown in the data limits a more detailed assessment.
Looking ahead, NeoPharm is positioned for moderate growth, supported by its strong cash flow generation and low debt profile. The company's operating cash flow of 28,409,737,460 KRW and free cash flow of 20,118,662,910 KRW provide a solid foundation for reinvestment and shareholder returns.
The risk assessment indicates a low probability of liquidity and dilution issues, with no immediate filing-based flags detected. The company's low debt levels and strong equity position further mitigate financial risk.
Recent investor relations data shows a mean price target of 24,000 KRW with a single buy recommendation, suggesting cautious optimism among analysts. However, the absence of strong buy ratings indicates a generally neutral sentiment rather than strong conviction in the company's near-term prospects.
- NeoPharm has a strong liquidity position with a current ratio of 8.4 and low debt-to-equity ratio of 0.01.
- The company's ROE of 14.24% and ROA of 12.77% indicate effective use of equity and assets to generate profits.
- Revenue is concentrated in the personal care products segment, with no disclosed geographic diversification.
- Analysts have a neutral outlook, with a mean price target of 24,000 KRW and one buy recommendation.
- The company's low liquidity and dilution risk, along with strong cash flow, supports its growth potential.
- **margin_outlook_rationale**: NeoPharm's gross profit margin is expected to remain stable due to consistent cost management and pricing power in the personal care products market.
- **rd_outlook_rationale**: The company is likely to maintain its R&D investment at current levels to sustain product innovation and market competitiveness.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 1 747,50 |
| Revenue | —no estimate | —no estimate | 146,6B KRW |
| Operating income | —no estimate | —no estimate | 33,3B KRW |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- NeoPharm Co Ltd Market data — financials · 2026-05-26
- NeoPharm Co Ltd Market data — analyst estimates · 2026-05-26